针对α-1抗素缺乏症的孤儿药物开发进展:FDA和EMA的2025年更新
Philipp Höger1, Markus Ries2, Arturo Olivares Rivera3
1Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Translational Lung Research Center (TLRC-H), German Center for Lung Research (DZL), Röntgenstraße 1, Heidelberg 69126, Germany.
Therapeutic advances in respiratory disease
|January 7, 2026
概括
这项研究审查了FDA和EMA对α-1抗素缺乏症 (AATD) 的孤儿药物批准. 虽然很少有AATD药物得到批准,但许多新疗法对肺部和其他器官表现有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 医学科学 医学科学 医学科学
背景情况:
- 40多年来,α-1抗素缺乏症 (AATD) 缺乏足够的安全有效的治疗方法.
- 患者需要方便的疗法,以解决AATD的肺和肺外表现.
研究的目的:
- 为FDA和EMA的孤儿药物批准和AATD化合物的名称提供定量临床监管概述.
- 分析目前AATD治疗开发的现状.
主要方法:
- 采用了横截面研究设计.
- 在FDA和EMA数据库中进行了全面的搜索,直到2025年1月,使用术语"抗素"和"蛋白酶".
- 主要终点:批准的孤儿药物的数量和性质;次要终点:孤儿药物名称.
主要成果:
- 美国食品和药物管理局在1987年批准了一种AATD药物,20种化合物获得了孤儿药物名称.
- 欧洲药物管理局已为AATD指定了9种活性物质,但尚未批准任何一种.
- 最近的指定包括新的疗法,如口服中性粒细胞弹性酶抑制剂,重组AAT,HSV载体疗法,A1AT调节剂和RNA干扰疗法.
结论:
- 新兴疗法有可能扩大AATD治疗选择.
- 未来的治疗可能会解决AATD的肺和肺外表现.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
1.5K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.5K
Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
Drug Administration and Therapy Phases: Overview
2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K
FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


